[Intravenous immunoglobulin treatment in children with PANS/PANDAS conditions]
Frønsdal KB, Grøvan A
Record ID 32018001081
Original Title: Behandling med intravenøs immunoglobulin ved PANS/PANDAS-tilstandene hos barn
Authors' objectives: To investigate the effect and safety of treatment with immunoglobulins in the conditions Pediatric Acute onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infection (PANDAS).
Authors' results and conclusions: RESULTS: Our findings are the following: No conlusion can be drawn on whether intravenous immunoglobulin has any effect on health-related quality of life as no study has reported data on this outcome. It is uncertain whether intravenous immunoglobulin improves level of functioning or symptoms (very low certainty of evidence, GRADE ⊕◯◯◯). Side-effects and adverse events can occur in line with the summary of product characteristics (low certainty of evidence GRADE ⊕⊕◯◯). Costs related to immunoglobulin treatment will vary considerably depending on dose and weight. As none of the human immunoglobulin preparations on the market have approved indication with specified dosage for the treatment of PANS/PANDAS, it is difficult to estimate what the costs will be if immunoglobulin treatment is introduced into the Norwegian clinical practice.
Project Status: Completed
Year Published: 2021
URL for published report: https://www.fhi.no/en/publ/2021/Intravenous-immunoglobulin-treatment-in-children-with-PANS-PANDAS-conditions/
English language abstract: An English language summary is available
Publication Type: Rapid Review
- Autoimmune Diseases
- Obsessive-Compulsive Disorder
- Immunoglobulins, Intravenous
- Immunologic Deficiency Syndromes
- Streptococcal Infections
- Treatment Outcome
- Costs and Cost Analysis
- Immunoglobulin G
Organisation Name: Norwegian Institute of Public Health
Contact Address: P.O. Box 222 Skoyen, N-0123, Oslo
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.